Search filters

Filters
Clear All

Phase

  • 1
  • 4
  • 3
  • 3
  • 13
  • 8
  • 13

Found 13 Pancreatic Cancer trials

A listing of Pancreatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 The Cancer of the Pancreas Screening-5
1 years - 99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
 Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism
1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
 Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer
99 years or below
All genders
Phase 1
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
99 years or below
All genders
Phase 2
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation
18 years - 99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
 A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
18 years - 99 years
All genders
Phase 1
Interventional
A study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
 A prospective  multi-center investigational study of IMMray
18 years - 99 years
All genders
Brief Summary: PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.
 Precision Promise Platform Trial for Metastatic Pancreatic Cancer
99 years or below
All genders
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
1 - 10 of 13